
Press Release

May 13, 2025

Sumitomo Pharma Co., Ltd.

**Notice Regarding the Estimated Recording of Gain
on Transfer of Shares in Affiliated Companies**

As announced on April 1, 2025, in the "Notice Regarding a Company Split (Simplified Absorption-Type Company Split) of the Asian Business and the Execution of a Share Transfer Agreement and a Shareholders' Agreement with Marubeni Global Pharma Corporation," Sumitomo Pharma Co., Ltd. (the "Company") has entered into a share transfer agreement and a shareholders' agreement with Marubeni Global Pharma Corporation. The share transfer agreement stipulates that the Asian business of the Company's wholly owned subsidiaries, Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd., along with their subsidiaries, will be transferred to a newly established wholly-owned subsidiary of the Company ("the new company") through an absorption-type company split, and that 60% of the newly issued shares of the new company will be transferred to Marubeni Global Pharma Corporation. The shareholders' agreement related to the new company includes the option for the remaining 40% of the shares of the new company held by the Company to be transferred to Marubeni Global Pharma Corporation.

Based on the currently available information, the Company has estimated the gain on transfer of shares in affiliated companies related to this transaction to be approximately 45 billion yen, and has factored it into the financial forecast for the fiscal year ending March 2026 announced today. The Company expects to record the said gain on transfer as "Other Income (Core)" in the second quarter of the fiscal year ending March 2026.

The estimated amount of the said gain on transfer is based on the information currently available and is not a finalized figure. The Company will promptly announce any matters that require disclosure if they arise in the future.

Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.

Contact:

Corporate Communications, Corporate Governance

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp